Lonza Group AG Stock
Your prediction
Lonza Group AG Stock
A loss of -1.780% shows a downward development for Lonza Group AG.
Pros and Cons of Lonza Group AG in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Cons
?
B****
?
M***** P*******
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Lonza Group AG vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Lonza Group AG | -1.780% | 2.925% | 2.057% | -2.198% | 4.453% | 103.087% | 106.201% |
| Novartis AG ADR | -0.720% | -0.730% | -1.449% | 36.546% | 14.768% | 42.558% | 74.359% |
| Novartis AG | -1.120% | -0.383% | -1.168% | 36.150% | 14.537% | 69.200% | 69.200% |
| Roche Holding AG ADR | -1.290% | 1.023% | 6.721% | 36.708% | 9.423% | 36.809% | 17.920% |
News
Lonza Delivered Strong H1 2026 Performance Across All Business Platforms and Upgrades Full-Year 2026 Margin Outlook
Lonza Delivered Strong H1 2026 Performance Across All Business Platforms and Upgrades Full-Year 2026 Margin Outlook
Lonza Expands Strategic Collaboration with Leading US Biopharmaceutical Company
Lonza Expands Strategic Collaboration with Leading US Biopharmaceutical Company
Lonza Expands HPAPI Capacity in Visp, Further Supporting its Position in Payload-Linker Manufacturing
Lonza Expands HPAPI Capacity in Visp, Further Supporting its Position in Payload-Linker Manufacturing